Geoffrey von Maltzahn

Geoffrey von Maltzahn is an American biological engineer and serial biotechnology entrepreneur. He is co-founder and chief executive officer of Lila Sciences, the autonomous AI-for-science company building scientific superintelligence platforms, and a general partner at Flagship Pioneering, the Cambridge venture-creation firm where he has originated companies since 2009. As of May 2026, von Maltzahn's co-founded companies include Generate Biomedicines, Tessera Therapeutics, Indigo Agriculture, Seres Therapeutics, Sana Biotechnology, and Quotient Therapeutics.

At a glance

• Education: B.S. in chemical engineering from the Massachusetts Institute of Technology (2003); M.S. in bioengineering from the University of California, San Diego (2005); Ph.D. from the Harvard-MIT Division of Health Sciences and Technology at MIT (2010), advised by Sangeeta Bhatia.
• Current role: Co-founder and chief executive officer of Lila Sciences, since 2023; general partner at Flagship Pioneering, since 2009; chief executive of Quotient Therapeutics; board chair of Tessera Therapeutics; chief innovation officer and board director of Indigo Agriculture; board director of Generate Biomedicines and Sana Biotechnology.
• Key contributions: Co-founder and founding chief executive of Indigo Agriculture (2014), Tessera Therapeutics (2018), Quotient Therapeutics (2023), and Lila Sciences (2023); co-founder of Seres Therapeutics (CTO 2010 to 2012), Cobalt Biomedicine (2016, merged into Sana Biotechnology in 2019), and Generate Biomedicines (2018); listed inventor on more than 200 patents.
• Recognition: Lemelson-MIT Student Prize (2009); National Inventors Hall of Fame Collegiate Inventors Competition Graduate Prize (2009); Randolph G. Wei Award for outstanding undergraduate research (2003).
• LinkedIn: geoffrey-von-maltzahn-7a6b755a
• Wikipedia: Geoffrey von Maltzahn

Origins

Von Maltzahn was born July 22, 1980 in Arlington, Texas, and raised in Alexandria, Virginia, where he attended Thomas Jefferson High School for Science and Technology. He earned a bachelor of science in chemical engineering from MIT in 2003, a master of science in bioengineering from the University of California, San Diego in 2005, and a Ph.D. from the Harvard-MIT Division of Health Sciences and Technology in 2010 in the laboratory of Sangeeta Bhatia.

The doctoral research developed tumor-targeted gold nanoparticles that convert infrared light to heat to ablate cancer cells, alongside synthetic nanoparticle communication systems for amplified drug delivery. The work attracted the inaugural Lemelson-MIT Student Prize and the National Inventors Hall of Fame Collegiate Inventors Competition Graduate Prize in 2009, alongside the Whitaker Foundation Doctoral Fellowship and an NSF Graduate Research Fellowship. While completing the doctorate, von Maltzahn co-founded Nanopartz Inc. (a Salt Lake City nanoparticle-platform company), Resonance Therapeutics (a Boston spinout for the photothermal-therapy work), and Sienna Labs (a plasmonic-particle dermatological company founded with two HST classmates).

Career

In November 2009, in the final year of his doctorate, von Maltzahn joined Flagship Pioneering as a VentureLabs Partner. Flagship is the Cambridge venture-creation firm founded by Noubar Afeyan, known for incubating Moderna and a portfolio of platform-biology companies. Von Maltzahn was promoted to general partner in 2020.

The Flagship origination work produced a sustained cadence of co-founded companies, with von Maltzahn typically serving as founding chief executive or chief technology officer through the early-stage build before transitioning to a board role. From 2010 to 2012 he was founding chief technology officer of Seres Therapeutics, leading the build-out of the microbiome-therapeutics platform and the discovery of SER-109, which became the first microbiome therapeutic to report positive Phase 3 clinical-trial data. Seres listed on Nasdaq as MCRB in June 2015.

In 2014 von Maltzahn co-founded Indigo Agriculture (launched as Symbiota) with Afeyan and other Flagship partners, serving as founding chief executive through 2017 and continuing as chief innovation officer and board director. Indigo applied plant-microbiome science to seed-coating treatments, launching Indigo Cotton in July 2016 and Wheat, Corn, and Soy thereafter.

In 2016 he co-founded Cobalt Biomedicine with Jacob Rubens, a Flagship Labs project developing Fusosome Therapeutics for intracellular delivery of nucleic-acid and protein drugs. Cobalt merged into Sana Biotechnology in early 2019; Sana listed on Nasdaq as SANA in February 2021.

In 2018 von Maltzahn co-founded Generate Biomedicines with Avak Kahvejian, Molly Gibson, and Gevorg Grigoryan to apply machine-learning methods to protein-therapeutics design. The same year, he co-founded Tessera Therapeutics, serving as founding chief executive through 2023 and continuing as board chair. Tessera developed the Gene Writing platform as a successor approach to gene editing.

In 2023 von Maltzahn co-founded Quotient Therapeutics with Jacob Rubens and Wellcome Sanger Institute academics Sir Mike Stratton, Iñigo Martincorena, and Peter Campbell, applying somatic-genomics methodology to therapeutic-target identification. The same year, he co-founded Lila Sciences with Afeyan, Gibson, and additional founding scientists including George Church and Andrew Beam. Lila operated in stealth through 2024 and emerged publicly on March 10, 2025 with a $200 million seed round and the stated mission of building scientific superintelligence across life, chemical, and materials sciences. A September 2025 Series A added $235 million at roughly $1.23 billion valuation, and an October 2025 extension of $115 million brought cumulative capital to $550 million.

Affiliations

• Flagship Pioneering: VentureLabs Partner, November 2009 to 2020; general partner, 2020 to present.
• Seres Therapeutics: Co-founder and chief technology officer, 2010 to 2012.
• Indigo Agriculture: Co-founder and founding chief executive, 2014 to 2017; chief innovation officer and board director, 2017 to present.
• Sana Biotechnology: Co-founder via Cobalt Biomedicine merger and board director, 2019 to present.
• Generate Biomedicines: Co-founder and board director, 2018 to present.
• Tessera Therapeutics: Co-founder and founding chief executive, 2018 to 2023; board chair, 2023 to present.
• Quotient Therapeutics: Co-founder and chief executive officer, 2023 to present.
• Lila Sciences: Co-founder and chief executive officer, 2023 to present.

Notable contributions

Von Maltzahn's public output is concentrated on the founding and operating leadership of multiple biotechnology and AI-for-science companies rather than on individual research authorship in the post-doctoral period.

• Doctoral nanomedicine research (2005 to 2010). Tumor-targeted gold-nanoparticle photothermal therapy and nanoparticle communication systems developed in the Sangeeta Bhatia laboratory. Recognized with the inaugural Lemelson-MIT Student Prize and the National Inventors Hall of Fame Collegiate Inventors Competition Graduate Prize in 2009.
• Seres Therapeutics SER-109 (2010 to 2012). Founding chief technology officer; the platform produced the first microbiome therapeutic to report positive Phase 3 clinical-trial data.
• Indigo Agriculture commercial launch (2014 to 2017). Founding chief executive; launched Indigo Cotton, Wheat, Corn, and Soy.
• Cobalt Biomedicine and Sana Biotechnology (2016 to 2019). Co-founder of the Fusosome Therapeutics platform; Cobalt merged into Sana in 2019, and Sana listed on Nasdaq as SANA in February 2021.
• Generate Biomedicines co-founding (2018). Co-founder of the machine-learning-driven protein-design company with Avak Kahvejian, Molly Gibson, and Gevorg Grigoryan.
• Tessera Therapeutics Gene Writing platform (2018). Founding chief executive through 2023; board chair thereafter.
• Quotient Therapeutics and Lila Sciences co-founding (2023). Chief executive of both. Lila raised $550 million cumulative across the March 2025 seed and the September and October 2025 Series A rounds.
• Patent portfolio. Listed inventor on more than 200 issued or pending patents across nanomedicine, microbiome therapeutics, gene editing, and machine-learning-driven biology.
• Public-talk record. Bloomberg Tech interview "Lila Wants to Create 'Scientific Superintelligence'" with Caroline Hyde and Ed Ludlow, September 15, 2025; ARK Invest For Your Innovation podcast with Brett Winton, April 17, 2025; EmTech MIT 2023 speaker appearance.

Investments and boards

The entries below are limited to AI, semiconductors, datacenters, software, and energy. Some are biotechnology companies covered for their software-and-AI character rather than drug-development pipelines.

• Flagship Pioneering (AI / Software): General partner, 2009 to present.
• Generate Biomedicines (AI): Co-founder and board director, 2018 to present. Machine-learning-driven protein-design platform.
• Tessera Therapeutics (AI / Software): Co-founder and board chair, 2018 to present. Gene Writing platform.
• Quotient Therapeutics (Software): Co-founder and chief executive officer, 2023 to present. Somatic-genomics platform.
• Lila Sciences (AI): Co-founder and chief executive officer, 2023 to present. Cumulative $550 million across the March 2025 seed and the 2025 Series A rounds.
• Sana Biotechnology (AI / Software): Co-founder via Cobalt Biomedicine and board director, 2019 to present. Listed on Nasdaq as SANA in February 2021.

No additional public personal angel-investor activity is on record in AI, semiconductors, datacenters, software, or energy as of May 2026.

Network

Von Maltzahn's longest-running professional relationship is with Noubar Afeyan, founder and chief executive of Flagship Pioneering, who has co-founded several of the companies (Indigo Agriculture, Lila Sciences, and others) for which von Maltzahn has served as founding chief executive. The Flagship general-partner cohort, including Avak Kahvejian, Molly Gibson, and Jacob Rubens, anchors the venture-creation network. The doctoral advising relationship with Sangeeta Bhatia at MIT shaped the early scientific direction.

At Lila Sciences, von Maltzahn's senior-team peers include George Church of Harvard Medical School and machine-learning lead Andrew Beam. Among AI-for-science peer founders, his position runs in parallel with Sam Rodriques and Andrew White at FutureHouse, Vik Bajaj at Project Prometheus, and the leadership at Isomorphic Labs, EvolutionaryScale, and Inceptive.

Position in the field

As of May 2026, von Maltzahn occupies a structurally distinctive position among AI-for-science chief executives through a sustained Flagship Pioneering origination record across nanomedicine, microbiome therapeutics, agricultural microbiomes, intracellular delivery, protein design, gene writing, and somatic genomics, capped by the transition to autonomous AI-for-science at Lila Sciences. The pattern of recurring founding-chief-executive roles followed by board transitions is characteristic of the Flagship Labs model.

The Flagship Pioneering site states that companies he has co-founded have aggregated more than $10 billion in cumulative public and private market capitalization. Holding the Lila chief-executive role alongside the Quotient chief-executive role and Tessera and Indigo board positions places him among a small group of biotechnology operators with simultaneous senior leadership across multiple companies. Most peer chief executives in frontier AI come from machine-learning backgrounds; peer AI-for-science chief executives such as Sam Rodriques at FutureHouse and Vik Bajaj at Project Prometheus come from bioengineering or physical-chemistry research. Von Maltzahn's nanomedicine doctoral record and the long Flagship platform-biology operating chronology is the principal difference, alongside the breadth of the Lila thesis across life, chemical, and materials sciences.

Outlook

Open questions over the next 6 to 18 months:

• Lila Sciences first commercial output. Whether the company ships any public-facing demonstration in life, chemical, or materials sciences, and the form of the first commercial partnership.
• Series B timing and structure. The timing and lead investor of the next Lila financing after the cumulative $550 million across the seed and Series A rounds.
• Quotient Therapeutics platform progress. Pipeline-development pace and any leadership transitions at Quotient as von Maltzahn balances the dual chief-executive load.
• Generate Biomedicines and Tessera Therapeutics trajectories. Progress of Generate's protein-design pipeline and the Tessera Gene Writing program through clinical-development milestones.
• Flagship origination cadence. Whether new venture creations continue at the historical rate or shift toward autonomous AI-for-science companies in the Lila mold.
• Public-commentary cadence. Frequency and substance of conference appearances and podcast interviews as Lila moves toward first commercial release.

Sources

• Geoffrey von Maltzahn. Wikipedia biographical entry covering education, Flagship tenure, and the co-founded companies.
• Geoffrey von Maltzahn at Flagship Pioneering. Flagship executive bio with the cumulative-capitalization figure and ventured-companies list.
• Geoffrey von Maltzahn at Tessera Therapeutics. Tessera leadership bio with patent count and platform narrative.
• Geoffrey von Maltzahn at Sana Biotechnology. Sana board-member bio on the Cobalt Biomedicine co-founding and merger.
• MEMP Alumni Profile: Geoffrey A. von Maltzahn, PhD, '10. Harvard-MIT HST alumni profile on the doctoral period and the Flagship VentureLabs role.
• Geoffrey von Maltzahn Lemelson-MIT Student Prize. Lemelson-MIT 2009 prize page on the doctoral nanomedicine research and Nanopartz and Resonance Therapeutics.
• Flagship Pioneering Unveils Lila Sciences. March 10, 2025 Flagship press release announcing Lila Sciences with a $200 million seed round.
• Announcing the close of the Lila Series A. October 10, 2025 Lila announcement of the $350 million combined Series A.
• Lila Sciences raises $200M to accelerate autonomous scientific research. SiliconANGLE coverage of the March 2025 seed round.
• Flagship VentureLabs Introduces Symbiota. November 2014 press release announcing the company that became Indigo Agriculture.
• Generate Biomedicines: Machine Learning-Powered Platform. Generate launch materials listing the founders.
• Flagship Pioneering Unveils Quotient Therapeutics. November 2023 press release announcing Quotient with von Maltzahn as chief executive.
• Lila Wants to Create 'Scientific Superintelligence'. Bloomberg Tech interview, September 15, 2025.
• How Lila Is Redefining Scientific Discovery With Geoffrey von Maltzahn. ARK Invest podcast, April 17, 2025.
• Photo: Geoffrey von Maltzahn at Flagship Pioneering, Flagship executive bio page.